Subscribe
Home
Issues
Online First
2023
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Authors
William King
Authored Items
Addressing Health Equity in Bladder Cancer Care
By
William King
TON - June 2023 Vol 16, No 3
Healthcare Equity
,
ASCO 2023 GU
,
Bladder Cancer
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
Online First
NCCN 2023 Conference Highlights
,
Lymphoma
,
Leukemia
,
Hematologic Malignancies
In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including
IGHV
gene status, 17p deletion/
TP53
mutation status, age, patient comorbidities, and resistance mutations.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Online First
NCCN 2023 Conference Highlights
,
Renal-Cell Carcinoma
,
Genitourinary Cancers
,
Kidney Cancer
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
Online First
NCCN 2023 Conference Highlights
,
Brain Cancer
Molecular/genetic characterization has taken on greater importance in the classification of adult gliomas and in diagnostic and treatment decision-making. “These tumors are now grouped and predicated more on molecular features rather than histopathologic criteria,” said L. Burt Nabors, MD, in a presentation during the 2023 National Comprehensive Cancer Network Annual Conference.
Updated Data Confirm Survival Benefit with Darolutamide in Metastatic Prostate Cancer
By
William King
TON - April 2023 Vol 16, No 2
ASCO 2023 GU
,
Genitourinary Cancers
,
Prostate Cancer
An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease, contributing to the evidence that this combination should be considered the new standard of care for this patient population.
Choosing the Best Adjuvant Therapy for Patients with RCC Requires Careful Consideration of Risks and Benefits
By
William King
TON - April 2023 Vol 16, No 2
Genitourinary Cancers
,
Renal-Cell Carcinoma
,
ASCO 2023 GU
The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Ribociclib plus Endocrine Treatment Outperforms Chemotherapy in Advanced Breast Cancer
By
William King
TON - February 2023 Vol 16, No 1
Breast Cancer
,
SABCS
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, including those with visceral crises, treated with the CDK4/6 inhibitor ribociclib (Kisqali) plus endocrine therapy had a significantly longer progression-free survival (PFS) and fewer adverse events (AEs) compared with those treated with combination chemotherapy, according to results from the phase 2 RIGHT Choice trial.
CTC Count May Help Providers Choose Optimal Therapy for Patients with Metastatic Breast Cancer
By
William King
TON - February 2023 Vol 16, No 1
SABCS
,
Breast Cancer
Using circulating tumor cell (CTC) count to guide the choice of first-line treatment—chemotherapy or endocrine therapy—improved overall survival (OS) compared with investigator’s choice of treatment for patients with metastatic, estrogen receptor (ER)-positive,
HER2
-negative breast cancer, according to results from the STIC CTC trial, which were discussed at the 2022 San Antonio Breast Cancer Symposium (SABCS) by François-Clément Bidard, MD, PhD, Co-Coordinator, Breast Cancer Research, Institut Curie, Paris, France, and Professor, Medicine, Department of Medical Oncology, Institut Curie and Université de Versailles Saint-Quentin-en-Yvelines, France.
Addition of Capivasertib to Fulvestrant Improves Outcomes in Metastatic Breast Cancer
By
William King
TON - February 2023 Vol 16, No 1
SABCS
,
Breast Cancer
In patients with hormone receptor (HR)-positive,
HER2
-low or -negative, locally advanced or metastatic breast cancer resistant to aromatase inhibitors, the addition of the investigational first-in-class AKT inhibitor capivasertib (AZD5363) to fulvestrant (Faslodex) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with placebo plus fulvestrant. The PFS benefit observed with capivasertib was even greater in a subset of patients with an AKT pathway alteration.
Strategies for Minimizing Some of the Most Distressing Symptoms of Cancer and Its Treatment
By
William King
TON - October 2022 Vol 15, No 5
ESMO
Minimizing some of the most distressing symptoms of cancer and its treatment requires systematic screening and risk assessment, as well as a focus on the underlying cause of these symptoms, according to experts at the European Society for Medical Oncology (ESMO) Congress 2022.
CAR T-Cell Effective as Second-Line Treatment in Transplant- Ineligible Large B-Cell Lymphoma
By
William King
TON - October 2022 Vol 15, No 5
Hematologic Malignancies
More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi).
Supporting and Empowering Young Oncology Nurses Academically, Clinically, and Professionally
By
William King
TON - October 2022 Vol 15, No 5
ESMO
During a special symposium at the European Society for Medical Oncology Congress 2022, a panel of experts identified some of the key challenges facing young oncology nurses and discussed strategies to better support and empower these professionals academically, clinically, and professionally.
Key Factors Associated with Early Discontinuation of Abemaciclib in Patients with Breast Cancer in the MonarchE Trial
By
William King
TON - October 2022 Vol 15, No 5
Breast Cancer
Several baseline factors were associated with an increased risk for early treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive,
HER2
-negative early breast cancer, according to findings from a multivariate analysis presented during the 2022 American Society of Clinical Oncology Annual Meeting.
Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups
By
William King
TON - October 2022 Vol 15, No 5
Cervical Cancer
The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.
ASCO President Stresses the Importance of Innovation for Advancing Equitable Cancer Care
By
William King
TON - August 2022 Vol 15, No 4
Healthcare Equity
The theme for the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting selected by 2021-2022 ASCO President Everett E. Vokes, MD, John E. Ultmann Professor of Medicine, and Chair, Department of Medicine, University of Chicago Duchossois Center for Advanced Medicine, Hyde Park, was advancing equitable cancer care through innovation.
Trastuzumab Deruxtecan Is a New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
By
William King
TON - August 2022 Vol 15, No 4
Breast Cancer
Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Telehealth Is Here to Stay, but Challenges Remain
By
William King
TON - June 2022 Vol 15, No 3
NCCN
Telehealth is playing a larger role in the delivery of cancer care, but there is more work that needs to be done to permanently increase access, according to a panel of experts during a plenary session at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference.
Updates to Screening and Surveillance Recommendations for Colorectal Cancer
By
William King
TON - June 2022 Vol 15, No 3
NCCN
Updates to the screening guidelines for colorectal cancer (CRC) from the National Comprehensive Cancer Network (NCCN) include lowering the initial screening age for average-risk individuals and second- and third-degree family members with CRC, as well as an extension in the interval for surveillance colonoscopy for low-risk individuals.
Nivolumab plus Ipilimumab Shows Promising Activity in the Neoadjuvant Setting for Patients with MSI/dMMR Oeso-Gastric Adenocarcinoma
By
William King
TON - June 2022 Vol 15, No 3
Gastrointestinal Cancers
Treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the neoadjuvant setting plus adjuvant nivolumab resulted in a high rate of pathologic complete response (pCR) in patients with resectable microsatellite instable (MSI)/mismatch repair deficient (dMMR) oeso-gastric junction (OGJ) adenocarcinoma, according to findings from the GERCOR NEONIPIGA clinical trial, which were presented by Thierry André, MD, Professor, Medical Oncology, Sorbonne Université, Hôpital Saint Antoine, Paris, France, at the 2022 ASCO Gastrointestinal Cancers Symposium.
Pembrolizumab Added to Best Supportive Care Improves Outcomes in Patients with Hepatocellular Carcinoma
By
William King
TON - June 2022 Vol 15, No 3
Hepatocellular Carcinoma
Pembrolizumab (Keytruda) added to best supportive care (BSC) improved outcomes including overall survival (OS) versus BSC alone in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib (Nexavar), according to final results from the KEYNOTE-394 trial.
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
By
William King
TON - June 2022 Vol 15, No 3
Prostate Cancer
Treatment with the androgen receptor inhibitor darolutamide (Nubeqa), in combination with androgen-deprivation therapy (ADT) and docetaxel, significantly improved overall survival (OS) compared with ADT and docetaxel alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent results from the phase 3 ARASENS clinical trial, which were simultaneously published in the
New England Journal of Medicine
.
Isatuximab plus RVd Achieves Highest Rates of No MRD in Multiple Myeloma
By
William King
TON - April 2022 Vol 15, No 2
ASH
,
Hematologic Malignancies
The addition of isatuximab (Sarclisa) to the triplet of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd) achieved superior minimal residual disease (MRD) negativity rates versus standard therapy with RVd alone as induction treatment in transplant-eligible patients with newly diagnosed multiple myeloma, according to results of the phase 3 GMMG-HD7 clinical trial presented at the 2021 ASH Annual Meeting and Exposition.
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
By
William King
TON - April 2022 Vol 15, No 2
ASCO
,
Gastrointestinal Cancers
Trastuzumab deruxtecan (Enhertu; T-DXd) continues to show superior antitumor activity and improved survival compared with standard chemotherapy in patients with advanced
HER2
-expressing gastric or gastroesophageal junction (GEJ) cancer, according to updated results from the phase 2 DESTINY-Gastric01 trial.
Novel Vaccine plus Chemotherapy Shows Promise in the Treatment of Metastatic Pancreatic Cancer
By
William King
TON - April 2022 Vol 15, No 2
ASCO
Interim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 superagonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer.
AK104 plus Chemotherapy Potential New First-Line Treatment for Patients with Advanced Gastric Cancer
By
William King
TON - April 2022 Vol 15, No 2
ASCO
Continuous Enzalutamide Reduces Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
By
William King
TON - April 2022 Vol 15, No 2
ASCO
Continuous enzalutamide (Xtandi) treatment in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer who had disease progression on enzalutamide alone, according to results from the phase 3b PRESIDE clinical trial.
Neoadjuvant Enfortumab Vedotin Appears Promising in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin
By
William King
TON - April 2022 Vol 15, No 2
ASCO
Neoadjuvant enfortumab vedotin (Padcev) showed promising antitumor activity in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin therapy, according to preliminary findings from cohort H of the phase 1b/2 EV-103 clinical trial.
Neoadjuvant Checkpoint Inhibitor plus TKI for Localized RCC: Encouraging Disease-Free Survival
By
William King
TON - April 2022 Vol 15, No 2
ASCO
The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial.
Community Providers Share Their Perspectives on Current and Future State of Cancer Care
By
William King
TON - April 2022 Vol 15, No 2
AVBCC Summit Highlights
Community-based providers remain at the core of the oncology care delivery system. A panel moderated by Barbara McAneny, MD, Chief Executive Officer, New Mexico Oncology Hematology Consultants, Albuquerque, at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021 explored the road ahead for community practices in terms of balancing value and delivering optimal access to care for patients.
The Future of Genetic Therapies and Value-Based Care in Oncology
By
William King
TON - April 2022 Vol 15, No 2
AVBCC Summit Highlights
With better insights into the biology of cancer and other diseases, genetic medicine is entering “a whole new ballgame,” said Scott Gottlieb, MD, Former FDA Commissioner, during the keynote session at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021.
Novel CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
By
William King
TON - December 2021 Vol 14, No 6
Hematologic Malignancies
A single dose of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen–directed CAR T-cell therapy, resulted in early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma, according to updated results from the phase 1b/2 CARTITUDE-1 clinical trial.
Early Phase 3 Trial Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced ESCC
By
William King
TON - December 2021 Vol 14, No 6
Gastrointestinal Cancers
Early results from the CheckMate-648 clinical trial, which evaluated the efficacy and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, suggest a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC).
Olaparib Prolongs Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
By
William King
TON - December 2021 Vol 14, No 6
Breast Cancer
The use of the PARP inhibitor olaparib (Lynparza) for 1 year after receiving standard chemotherapy in the neoadjuvant or the adjuvant setting significantly improved invasive disease-free survival in patients with high-risk, early-stage,
HER2
-negative breast cancer and
BRCA1
or
BRCA2
mutations, according to results presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
New Saliva Test Can Be Used to Detect HPV-Associated Head and Neck Cancer
By
William King
TON - December 2021 Vol 14, No 6
Head and Neck Cancer
Balstilimab Shows Promising Activity in Patients with Advanced Cervical Cancer
By
William King
TON - December 2021 Vol 14, No 6
Cervical Cancer
According to results from a recent study, balstilimab, an investigational PD-1 inhibitor, demonstrated meaningful and durable clinical activity in patients with recurrent or metastatic cervical cancer. These findings were presented by Cailin E. Joyce, MD, Director, Applied Technology, Agenus, Boston, MA, during the American Society of Clinical Oncology 2021 virtual annual meeting.
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
By
William King
TON - October 2021 Vol 14, No 5
Melanoma
The addition of the lymphocyte activation gene-3 (
LAG-3
)-blocking antibody relatlimab to nivolumab (Opdivo) led to significantly longer progression-free survival (PFS) compared with nivolumab alone in previously untreated patients with advanced melanoma, according to results of the phase 3 RELATIVITY-047 clinical trial presented at the American Society of Clinical Oncology 2021 virtual annual meeting.
Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer
By
William King
TON - June 2021 Vol 14, No 3
Ovarian Cancer
Despite improvements in the treatment of advanced ovarian cancer, less than half of newly diagnosed patients survive longer than 5 years, and relapse rates remain high. At the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, experts presented updated results from 2 phase 3 clinical trials showing the benefit of the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib (Lynparza) and niraparib (Zejula) as maintenance therapy in women with advanced or recurrent disease.
CD73 Inhibitor–Based Combination Therapy Induces Responses in Patients with Metastatic Pancreatic Cancer
By
William King
TON - June 2021 Vol 14, No 3
Pancreatic Cancer
A small-molecule CD73 inhibitor (AB680) induced a 41% overall response rate (ORR) when combined with chemotherapy (with nab-paclitaxel and gemcitabine), plus the novel PD-1 inhibitor zimberelimab, as a first-line treatment for patients with metastatic pancreatic cancer according to results of the dose-escalation portion of the phase 1/1b ARC-8 study.
Pevonedistat plus Azacitidine Combination Shows Encouraging Activity in Higher-Risk MDS
By
William King
TON - April 2021 Vol 14, No 2
Hematologic Malignancies
The combination of the investigational drug pevonedistat in combination with azacitidine injection (Vidaza) leads to longer event-free survival (EFS) and a higher complete response rate than azacitidine alone in patients with high-risk myelodysplastic syndromes (MDS), according to results from a phase 2, open-label, international clinical trial.
Belantamab Induces Clinically Meaningful Responses in Heavily Pretreated Patients with Multiple Myeloma
By
William King
TON - February 2021 Vol 14, No 1
ASH 2020 Highlights
,
Multiple Myeloma
A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Novel Drug Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL
By
William King
TON - December 2020, Vol 13, No 6
NCCN
AACR’s Cancer Disparities Inaugural Report Highlights Need for Healthcare Equity
By
William King
TON - October 2020, Vol 13, No 5
Disparities in Oncology
Cancer health disparities remain a challenge in the United States, despite some strides being made to reduce these disparities, according to a new report from the American Association for Cancer Research (AACR) that was released in a virtual presentation on September 16, 2020.
Adavosertib Monotherapy Demonstrates Promising Clinical Activity in Uterine Serous Cancer
By
William King
TON - August 2020, Vol 13, No 4
Emerging Therapies
The small molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. The responses were durable, with a median duration of response of 9.03 months.
Capmatinib Shows Promise in MET-Amplified Non–Small- Cell Lung Cancer
By
William King
TON - August 2020, Vol 13, No 4
Lung Cancer
Capmatinib (Tabrecta), an oral kinase inhibitor, has shown clinical activity in patients with high-level MET-amplified advanced non–small-cell lung cancer (NSCLC), according to new data presented at the ASCO 2020 virtual annual meeting.
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma
By
William King
TON - August 2020, Vol 13, No 4
Hematologic Cancers
A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
Actionable Alterations Are Few in Renal-Cell Carcinoma
By
William King
TON - August 2020, Vol 13, No 4
AUA Highlights
There has been increased focus on the study of tumor alterations that may predict treatment benefit or serve as possible actionable targets for new therapeutic approaches in cancer.
ctDNA Alterations Correlate with Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
By
William King
TON - August 2020, Vol 13, No 4
AUA Highlights
Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA.
Chemoimmunotherapy Combo Shows Efficacy in Patients with Advanced Urothelial Cancer
By
William King
TON - August 2020, Vol 13, No 4
AUA Highlights
Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma.
Pembrolizumab plus Enzalutamide Shows Activity in Metastatic Castration-Resistant Prostate Cancer
By
William King
TON - August 2020, Vol 13, No 4
AUA Highlights
Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting.
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
Categories
Conference Correspondent
ONS 2023 - Multiple Myeloma: Wrap-Up
LBCL 2022 - Year in Review
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION